RxDoctor Payments Data

Donna Colquhoun

Family · Madison, CTNPI 1548457260

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 426 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,157in general payments, 2019–2025

Across 426 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$793
  • Johnson & Johnson$596
  • Amgen$580
  • Lilly USA, LLC$490
  • Sanofi$464
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$8,07799%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,157 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$106,102
Medicare patients
496
Services billed
1,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa13$283,480
Betamethasone Dipropionate106$6,662
Ivermectin11$2,758
Doxycycline Hyclate85$2,046
Ciclopirox57$1,695
Tacrolimus11$1,576
Clobetasol Propionate42$1,563
Alclometasone Dipropionate61$1,546
Ketoconazole81$1,465
Metronidazole23$1,144
Fluticasone Propionate50$1,029
Triamcinolone Acetonide21$510
Mupirocin56$430
Clindamycin Phosphate14$406
Minocycline Hcl13$359

Paid to pharmacies, not to this prescriber.

Other family in Madison

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →